Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05248009 · ClinicalTrials.gov registry record · NA
Feasibility of Semi-Permanent Tattoo for Treatment Alignment in Radiation Therapy
A NA study of Cancer, Treatment-Related and Tattoo; Pigmentation, sponsored by Henry Ford Health System.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05248009: Completed NA study of Cancer, Treatment-Related and Tattoo; Pigmentation, sponsored by Henry Ford Health System.
NCT05248009 is a NA study of Cancer, Treatment-Related and Tattoo; Pigmentation that has completed, run by Henry Ford Health System. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05248009, a NA study of Cancer, Treatment-Related and Tattoo; Pigmentation, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Consenting subjects will receive a semi-permanent tattoo in place of the standard of care permanent tattoo for radiation marking at the time of the radiation planning scan. Subjects will be monitored to ensure alignment is the same with the semi-permanent tattoo as the current standard of care. Subjects will be monitored to ensure there are no skin reactions or other side effects. Subjects will be followed for 15 months and will send pictures to the treatment team to ensure that the tattoo fades away within 12 months as expected.
Primary Outcome
Adverse events related to the tattooing process including skin toxicity during the completion of radiation therapy will be assessed using Common Terminology Criteria for Adverse Events (CTCAE v5). The type, incidence, severity, timing, serious, and relatedness of AE and laboratory abnormalities will be reported and tabulated. The CTCAE is assessed according to grades 1-5, where grade 5 constitutes the highest severity and worse outcome.
Conditions Studied
Interventions
- DEVICE Semi-Permanent Tattoo Ink
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2024-09-01 |
| Phase | NA |
What the finished NCT05248009 record still lists
NCT05248009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Cancer, Treatment-Related appearing as the primary indexed condition, and to 1 intervention - of which Semi-Permanent Tattoo Ink is the first listed.
NCT05248009 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05248009 about?
NCT05248009 is a clinical study titled "Feasibility of Semi-Permanent Tattoo for Treatment Alignment in Radiation Therapy". Consenting subjects will receive a semi-permanent tattoo in place of the standard of care permanent tattoo for radiation marking at the time of the radiation planning scan. Subjects will be monitored to ensure alignment is the same with the semi-permanent tattoo as the current standard of care. Subj...
What is the current status of trial NCT05248009?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2022-06-23. Estimated completion is 2024-09-01.
What conditions does trial NCT05248009 study?
This clinical trial studies the following conditions: Cancer, Treatment-Related, Tattoo; Pigmentation.
What interventions are being tested in trial NCT05248009?
The interventions under investigation include: Semi-Permanent Tattoo Ink (DEVICE).
Who is sponsoring clinical trial NCT05248009?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05248009 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer, Treatment-Related
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05248009's enrollment target sits among peer trials
15 1881st of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI